New hope for Tough-to-Treat blood disorder
NCT ID NCT06569147
Summary
This study is testing an experimental drug called elranatamab in people with AL amyloidosis that has returned or hasn't responded to previous treatments. The research aims to find the safest and most effective dose and see how well the drug controls the disease. About 49 participants will receive the drug through injections over several months while doctors monitor their response and any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.